AR090056A1 - Anticuerpos anti-cxcr3 - Google Patents
Anticuerpos anti-cxcr3Info
- Publication number
- AR090056A1 AR090056A1 ARP130100184A ARP130100184A AR090056A1 AR 090056 A1 AR090056 A1 AR 090056A1 AR P130100184 A ARP130100184 A AR P130100184A AR P130100184 A ARP130100184 A AR P130100184A AR 090056 A1 AR090056 A1 AR 090056A1
- Authority
- AR
- Argentina
- Prior art keywords
- cxcr3
- antibodies
- cxcr3 antibodies
- diagnose
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588936P | 2012-01-20 | 2012-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090056A1 true AR090056A1 (es) | 2014-10-15 |
Family
ID=47633576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100184A AR090056A1 (es) | 2012-01-20 | 2013-01-21 | Anticuerpos anti-cxcr3 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8865870B2 (https=) |
| EP (1) | EP2804878B1 (https=) |
| JP (3) | JP6352812B6 (https=) |
| KR (2) | KR102073034B1 (https=) |
| CN (1) | CN104507967B (https=) |
| AR (1) | AR090056A1 (https=) |
| AU (1) | AU2013209492B2 (https=) |
| BR (1) | BR112014017814A8 (https=) |
| CA (1) | CA2862222A1 (https=) |
| CY (1) | CY1121335T1 (https=) |
| DK (1) | DK2804878T3 (https=) |
| ES (1) | ES2698606T3 (https=) |
| HR (1) | HRP20181874T1 (https=) |
| HU (1) | HUE041900T2 (https=) |
| IL (2) | IL233694A0 (https=) |
| LT (1) | LT2804878T (https=) |
| MX (1) | MX359854B (https=) |
| PL (1) | PL2804878T3 (https=) |
| PT (1) | PT2804878T (https=) |
| RS (1) | RS58141B1 (https=) |
| RU (1) | RU2663141C2 (https=) |
| SG (2) | SG10201700735PA (https=) |
| SI (1) | SI2804878T1 (https=) |
| TW (1) | TWI596112B (https=) |
| UY (1) | UY34582A (https=) |
| WO (1) | WO2013109974A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| WO2016028523A2 (en) | 2014-08-22 | 2016-02-25 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind cxcr3 |
| CA3003458A1 (en) | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
| EP3464349A4 (en) * | 2016-05-23 | 2020-08-26 | New York University | COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS |
| EP3559036A1 (en) * | 2016-12-22 | 2019-10-30 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
| KR20190095943A (ko) * | 2016-12-22 | 2019-08-16 | 사노피 | 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법 |
| TW201840585A (zh) | 2016-12-22 | 2018-11-16 | 法商賽諾菲公司 | 用於白斑病的治療的抗人cxcr3抗體 |
| WO2019158675A1 (en) * | 2018-02-16 | 2019-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating vitiligo |
| KR102074798B1 (ko) * | 2018-06-15 | 2020-02-07 | 코아스템(주) | 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도 |
| EP3880239A4 (en) | 2018-11-14 | 2022-11-23 | Arch Oncology, Inc. | THERAPEUTIC SIRPalpha ANTIBODIES |
| SG11202110145SA (en) | 2020-02-26 | 2021-10-28 | Vir Biotechnology Inc | Antibodies against sars-cov-2 and methods of using the same |
| CN116234572A (zh) * | 2020-04-30 | 2023-06-06 | 安驰肿瘤公司 | 治疗性SIRPα抗体 |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| JP2024508304A (ja) * | 2021-03-02 | 2024-02-26 | ノヴァロック バイオセラピューティクス， リミテッド | Ｃｌａｕｄｉｎ－６に対する抗体およびそれの使用 |
| EP4384218A4 (en) * | 2021-08-09 | 2025-11-05 | Merck Patent Gmbh | Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| CN120112292A (zh) | 2022-09-09 | 2025-06-06 | 爱杜西亚药品有限公司 | 包含抗-cd3抗体及cxcr3拮抗剂的药物组合 |
| WO2025185738A1 (zh) * | 2024-03-08 | 2025-09-12 | 演生潮(北京)生物科技有限公司 | 靶向cxcr3的抗原结合蛋白及其应用 |
| WO2026069312A1 (en) | 2024-09-24 | 2026-04-02 | Yeda Research And Development Co. Ltd. | Immune cells expressing an inducible therapeutic agent and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565332A (en) | 1896-08-04 | Toy for making soap-bubbles | ||
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| JP2826272B2 (ja) | 1993-10-26 | 1998-11-18 | タイガースポリマー株式会社 | 中空樹脂成形品の製造装置及び製造方法 |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| EP0925358B1 (en) * | 1996-09-10 | 2007-04-25 | Theodor-Kocher Institute | Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use |
| US6140064A (en) * | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2001072334A2 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Methods for treating disease with antibodies to cxcr3 |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| MXPA06000252A (es) * | 2003-06-30 | 2006-12-15 | Bio Technology General Israel | Anticuerpos y usos de los mismos. |
| WO2005030793A2 (en) * | 2003-09-24 | 2005-04-07 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
| ATE557042T1 (de) * | 2004-03-23 | 2012-05-15 | Lilly Co Eli | Anti-myostatin-antikörper |
| BRPI0514259A (pt) | 2004-08-11 | 2008-06-03 | Trubion Pharmaceuticals Inc | proteìna de fusão de domìnio de ligação |
| BRPI0710011A2 (pt) | 2006-04-14 | 2011-08-02 | Trubion Pharmaceuticals Inc | proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas |
| US8435522B2 (en) * | 2007-02-01 | 2013-05-07 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against CXCR3 |
| CN111909273B (zh) | 2007-08-29 | 2024-03-26 | 塞诺菲-安万特股份有限公司 | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 |
| US20100130476A1 (en) | 2008-11-12 | 2010-05-27 | The Scripps Research Institute | Compounds that induce pancreatic beta-cell expansion |
| WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| CA2789963C (en) * | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
-
2013
- 2013-01-18 SG SG10201700735PA patent/SG10201700735PA/en unknown
- 2013-01-18 CA CA2862222A patent/CA2862222A1/en not_active Abandoned
- 2013-01-18 KR KR1020147023225A patent/KR102073034B1/ko not_active Expired - Fee Related
- 2013-01-18 RS RS20181422A patent/RS58141B1/sr unknown
- 2013-01-18 RU RU2014134043A patent/RU2663141C2/ru active
- 2013-01-18 PL PL13702548T patent/PL2804878T3/pl unknown
- 2013-01-18 HU HUE13702548A patent/HUE041900T2/hu unknown
- 2013-01-18 SG SG11201406762QA patent/SG11201406762QA/en unknown
- 2013-01-18 WO PCT/US2013/022280 patent/WO2013109974A2/en not_active Ceased
- 2013-01-18 AU AU2013209492A patent/AU2013209492B2/en not_active Ceased
- 2013-01-18 JP JP2014553482A patent/JP6352812B6/ja not_active Expired - Fee Related
- 2013-01-18 CN CN201380015401.8A patent/CN104507967B/zh not_active Expired - Fee Related
- 2013-01-18 KR KR1020207002561A patent/KR20200014441A/ko not_active Ceased
- 2013-01-18 DK DK13702548.2T patent/DK2804878T3/en active
- 2013-01-18 HR HRP20181874TT patent/HRP20181874T1/hr unknown
- 2013-01-18 BR BR112014017814A patent/BR112014017814A8/pt not_active Application Discontinuation
- 2013-01-18 EP EP13702548.2A patent/EP2804878B1/en active Active
- 2013-01-18 US US13/745,377 patent/US8865870B2/en not_active Expired - Fee Related
- 2013-01-18 ES ES13702548T patent/ES2698606T3/es active Active
- 2013-01-18 SI SI201331249T patent/SI2804878T1/sl unknown
- 2013-01-18 PT PT13702548T patent/PT2804878T/pt unknown
- 2013-01-18 LT LTEP13702548.2T patent/LT2804878T/lt unknown
- 2013-01-18 MX MX2014008728A patent/MX359854B/es active IP Right Grant
- 2013-01-21 TW TW102102282A patent/TWI596112B/zh not_active IP Right Cessation
- 2013-01-21 AR ARP130100184A patent/AR090056A1/es unknown
- 2013-01-21 UY UY0001034582A patent/UY34582A/es not_active Application Discontinuation
-
2014
- 2014-07-17 IL IL233694A patent/IL233694A0/en unknown
- 2014-09-08 US US14/480,052 patent/US9765144B2/en not_active Expired - Fee Related
-
2017
- 2017-08-04 US US15/669,556 patent/US20180086838A1/en not_active Abandoned
-
2018
- 2018-05-07 JP JP2018089004A patent/JP6646100B2/ja not_active Expired - Fee Related
- 2018-09-14 US US16/132,333 patent/US20190119391A1/en not_active Abandoned
- 2018-11-22 CY CY20181101236T patent/CY1121335T1/el unknown
-
2019
- 2019-12-24 IL IL271697A patent/IL271697A/en unknown
-
2020
- 2020-01-08 JP JP2020001152A patent/JP2020072715A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090056A1 (es) | Anticuerpos anti-cxcr3 | |
| ECSP14013132A (es) | Anticuerpos anti-psgl-1 y usos de los mismos | |
| WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| MX375911B (es) | Constructos de anticuerpo multiespecifico. | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| AR103161A1 (es) | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso | |
| BR112016015936A2 (pt) | Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição | |
| AR088941A1 (es) | Anticuerpos anti-fgfr2 y sus usos | |
| HK1243333A1 (zh) | 用於修饰的t细胞的方法和组合物 | |
| BR112016030424A2 (pt) | construções de anticorpo multiespecíficas | |
| MX2015012862A (es) | Moleculas de union para bcma y cd3. | |
| BR112012004823A8 (pt) | Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica | |
| ECSP14004829A (es) | Moléculas de unión para bcma y cd3 | |
| PE20190229A1 (es) | Anticuerpos anti-fcrn | |
| MX2014008963A (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| MX2017007826A (es) | Proteina de fusion que conprende tres dominios de union a 5t4 y cd3. | |
| PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
| UY33588A (es) | Moleculas de union a vegf | |
| CL2012000524A1 (es) | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. | |
| UY32917A (es) | Moléculas de unión a dll-4 | |
| CL2016000438A1 (es) | Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica | |
| BR112014023415A2 (pt) | moléculas que se ligam a ang2 | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| MX355356B (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |